Warnex and Rosetta Genomics Announce Exclusive Distribution Agreement for Rosetta's microRNA-Based Assays in Canada
News Aug 17, 2009
Warnex Medical Laboratories, a division of Warnex Inc., and Rosetta Genomics, Ltd. have announced they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests.
Under the terms of the agreement, Warnex will market Rosetta Genomics' miRview™ tests. Samples will be sent from Canada to Rosetta Genomics' Philadelphia-based CLIA-certified laboratory for analysis. The terms of the deal were not disclosed.
"We are pleased to add these new tests to our growing portfolio of pharmacogenetic tests," said Mark Busgang, President & CEO of Warnex. "These tests offered by Rosetta Genomics will allow oncologists to accurately trace the origin of the tumor in the body and to better characterize the tissue type, which can lead to a more efficient chemotherapy treatment."
"We are excited to have a well established molecular diagnostic laboratory such as Warnex as our distribution partner in Canada, noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. "Canada is an important market, and this agreement is a significant step as we expand the market for our products in North America. This agreement joins our existing contracts with Prometheus Laboratories in the U.S., and with Teva Pharmaceuticals in Israel and Turkey. We continue in our efforts to expand our global distribution network to other parts of the world, and expect to have additional agreements in place in the near future."
The miRview™ tests leverage proprietary microRNA technology developed by Rosetta Genomics, and measure the expression level of specific microRNA biomarkers in tumor samples. The following tests will be distributed by Warnex:
• miRview™ mets - This test can accurately identify the primary tumor site in patients presenting with metastatic cancer, as well in patients whose tumor has not been identified, and consequently been labeled Cancer of Unknown Primary (CUP). As metastases need to be treated according to their primary origin, accurate identification of the metastases' primary origin can be critical for determining appropriate treatment.
• miRview™ squamous - Using a single microRNA, miRview™ squamous differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients. When administered targeted therapy, whether currently available or under development, patients with squamous cell carcinoma of the lung have demonstrated varying response patterns ranging from a high incidence of severe or fatal internal bleeding in the lungs to overall poor response to treatment.
• miRview™ meso - This test leverages microRNA's high specificity as biomarkers, to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung. As mesothelioma patients require specific treatment regimens, accurately diagnosing mesothelioma is critical. miRview™ meso may also assist physicians to rule out mesothelioma in patients diagnosed with adenocarcinoma in the lung who have been exposed to mesothelioma-related substances, primarily asbestos particles and heavy metals.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019